As Kaftrio, the revolutionary therapeutic that has radically improved the lives of many persons affected by CF, is a combination of CFTR modulators, specifically VX445 with corrector VX661 and potentiator VX770, we tested VX445’s capability to increase F508del CFTR channel activity when administrated in combination with the other correctors used in this study. This evidence concerns the gene CFTR and cystic fibrosis.